{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:12:53Z","timestamp":1793236373430,"version":"4.5.0"},"reference-count":177,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02653-x","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T06:26:23Z","timestamp":1754461583000},"page":"1927-1950","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Process to radioactive iodine treatment for Graves\u2019 hyperthyroidism: condemned or absolved?"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8447-5449","authenticated-orcid":false,"given":"Luigi","family":"Bartalena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Kahaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Piantanida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Tanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"16","key":"2653_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith TJ, Heged\u00fcs L (2016) Graves\u2019 disease. N Engl J Med 375(16):1552\u20131565. https:\/\/doi.org\/10.1056\/NEJMra1510030","journal-title":"N Engl J Med"},{"issue":"1","key":"2653_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","volume":"6","author":"TF Davies","year":"2020","unstructured":"Davies TF, Andersen S, Latif R, Nagayama Y, Barbesino G, Brito M et al (2020) Graves\u2019 disease. Nat Rev Dis Primers 6(1):52. https:\/\/doi.org\/10.1038\/s41572-020-0184-y","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"2653_CR3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40618-014-0097-2","volume":"37","author":"L Bartalena","year":"2014","unstructured":"Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of graves\u2019 disease: a 2014 update. J Endocrinol Invest 37(8):691\u2013700. https:\/\/doi.org\/10.1007\/s40618-014-0097-2","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"2653_CR4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41574-024-01016-5","volume":"20","author":"G Lanzolla","year":"2024","unstructured":"Lanzolla G, Marin\u00f2 M, Menconi F (2024) Graves disease: latest Understanding of pathogenesis and treatment options. Nat Rev Endocrinol 20(11):647\u2013660. https:\/\/doi.org\/10.1038\/s41574-024-01016-5","journal-title":"Nat Rev Endocrinol"},{"key":"2653_CR5","doi-asserted-by":"publisher","first-page":"1571427","DOI":"10.3389\/fimmu.2025.1571427","volume":"16","author":"ACH Lee","year":"2025","unstructured":"Lee ACH, Kahaly GJ (2025) Targeted immunotherapies for graves\u2019 thyroidal & orbital diseases. Front Immunol 16:1571427. https:\/\/doi.org\/10.3389\/fimmu.2025.1571427","journal-title":"Front Immunol"},{"issue":"12","key":"2653_CR6","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1210\/clinem\/dgaa64","volume":"105","author":"GJ Kahaly","year":"2020","unstructured":"Kahaly GJ (2020) Management of graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab 105(12):3704\u20133720. https:\/\/doi.org\/10.1210\/clinem\/dgaa64","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2653_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/17446651.2022.2052044","volume":"17","author":"L Bartalena","year":"2022","unstructured":"Bartalena L, Piantanida E, Gallo D, Ippolito S, Tanda ML (2022) Management of graves\u2019 hyperthyroidism: present and future. Expert Rev Endocrinol Metab 17(2):153\u2013166. https:\/\/doi.org\/10.1080\/17446651.2022.2052044","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"11","key":"2653_CR8","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1210\/clinem\/dgae222","volume":"109","author":"D Villagelin","year":"2024","unstructured":"Villagelin D, Cooper DS, Burch HB (2024) A 2023 international survey of clinical practice patterns in the management of graves disease: a decade of change. J Clin Endocrinol Metab 109(11):2956\u20132966. https:\/\/doi.org\/10.1210\/clinem\/dgae222","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2653_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3803\/EnM.2024.2093","volume":"40","author":"JA Kim","year":"2025","unstructured":"Kim JA, Kim KJ, Choi J, Kim KJ, Song E, Yu JH et al (2025) Unveiling risk factors for treatment failure in patients with graves\u2019 disease: a nationwide cohort study in Korea. Endocrinol Metab (Seoul) 40(1):125\u2013134. https:\/\/doi.org\/10.3803\/EnM.2024.2093","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2653_CR10","doi-asserted-by":"publisher","unstructured":"Atkinson M, Agrawal M, Muralidhara K, Abraham P, Vaidya B, Okosieme OE (2025) British Thyroid Association survey of Graves\u2019 disease management in the UK. Clin Endocrinol (Oxf) 2025 May 8. https:\/\/doi.org\/10.1111\/cen.15266. Online ahead of print","DOI":"10.1111\/cen.15266"},{"issue":"12","key":"2653_CR11","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1210\/jc.2012-2802","volume":"97","author":"HB Burch","year":"2012","unstructured":"Burch HB, Burman KD, Cooper DS (2012) A 2011 survey of clinical practice patterns in the management of graves\u2019 disease. J Clin Endocrinol Metab 97(12):4549\u20134558. https:\/\/doi.org\/10.1210\/jc.2012-2802","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2653_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/cen.12688","volume":"84","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Burch HB, Burman KD, Kahaly GJ (2016) A 2013 European survey of clinical practice patterns in the management of graves\u2019 disease. Clin Endocrinol (Oxf) 84(1):115\u2013120. https:\/\/doi.org\/10.1111\/cen.12688","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2653_CR13","doi-asserted-by":"publisher","first-page":"R261","DOI":"10.1530\/EJE-18-0678","volume":"179","author":"HB Burch","year":"2018","unstructured":"Burch HB, Cooper DS (2018) Anniversary review: antithyroid drug therapy: 70 years later. Eur J Endocrinol 179(5):R261\u2013R274. https:\/\/doi.org\/10.1530\/EJE-18-0678","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2653_CR14","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1089\/thy.2016.0652","volume":"27","author":"F Azizi","year":"2017","unstructured":"Azizi F, Malboosbaf R (2017) Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid 27(10):1223\u20131231. https:\/\/doi.org\/10.1089\/thy.2016.0652","journal-title":"Thyroid"},{"issue":"2","key":"2653_CR15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s12020-023-03656-5","volume":"84","author":"F Azizi","year":"2024","unstructured":"Azizi F, Amouzegar A, Khalili D, Abdi H, Tohidi M, Hedayati M et al (2024) Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with graves\u2019 hyperthyroidism: a randomized trial and a risk-scoring model. Endocrine 84(2):577\u2013588. https:\/\/doi.org\/10.1007\/s12020-023-03656-5","journal-title":"Endocrine"},{"issue":"10","key":"2653_CR16","doi-asserted-by":"publisher","first-page":"e1881","DOI":"10.1210\/clinem\/dgae456","volume":"109","author":"F Azizi","year":"2024","unstructured":"Azizi F, Mehran L, Abdi H, Amouzegar A (2024) Approach to the patient considering long-term antithyroid drug therapy for graves\u2019 disease. J Clin Endocrinol Metab 109(10):e1881\u2013e1888. https:\/\/doi.org\/10.1210\/clinem\/dgae456","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2653_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1530\/EC-21-0340","volume":"10","author":"X Wang","year":"2021","unstructured":"Wang X, Teng X, Li C, Li Y, Li J, Teng W et al (2021) A Chinese survey on clinical practice in hyperthyroidism management: comparison with recent studies and guidelines. Endocr Connect 10(9):1091\u20131100. https:\/\/doi.org\/10.1530\/EC-21-0340","journal-title":"Endocr Connect"},{"issue":"6","key":"2653_CR18","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJMct1007101","volume":"364","author":"DS Ross","year":"2011","unstructured":"Ross DS (2011) Radioiodine therapy for hyperthyroidism. N Engl J Med 364(6):542\u2013550. https:\/\/doi.org\/10.1056\/NEJMct1007101","journal-title":"N Engl J Med"},{"issue":"8","key":"2653_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrendo.2010.105","volume":"6","author":"B Biondi","year":"2010","unstructured":"Biondi B, Kahaly GJ (2010) Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol 6(8):431\u2013443. https:\/\/doi.org\/10.1038\/nrendo.2010.105","journal-title":"Nat Rev Endocrinol"},{"issue":"9285","key":"2653_CR20","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S0140-6736(01)06067-6","volume":"358","author":"JV Parle","year":"2001","unstructured":"Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA (2001) Prediction of all-cause and cardiovascular mortality in elderly people from one low serum Thyrotropin result: a 10-year cohort study. Lancet 358(9285):861\u2013865. https:\/\/doi.org\/10.1016\/S0140-6736(01)06067-6","journal-title":"Lancet"},{"issue":"7","key":"2653_CR21","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1210\/jc.2007-0179","volume":"92","author":"H V\u00f6lzke","year":"2007","unstructured":"V\u00f6lzke H, Schwahn C, Wallaschofski H, D\u00f6rr M (2007) The association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship? J Clin Endocrinol Metab 92(7):2421\u20132429. https:\/\/doi.org\/10.1210\/jc.2007-0179","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2653_CR22","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1001\/archinternmed.2012.402","volume":"172","author":"TH Collet","year":"2012","unstructured":"Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P et al (2012) Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 172(10):799\u2013809. https:\/\/doi.org\/10.1001\/archinternmed.2012.402","journal-title":"Arch Intern Med"},{"issue":"4","key":"2653_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-11-0299","volume":"165","author":"F Brandt","year":"2011","unstructured":"Brandt F, Green A, Heged\u00fcs L, Brix TH (2011) A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol 165(4):491\u2013497. https:\/\/doi.org\/10.1530\/EJE-11-0299","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2653_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1089\/thy.2012.0500","volume":"23","author":"F Brandt","year":"2013","unstructured":"Brandt F, Thvilum M, Almind D, Christensen K, Green A, Heged\u00fcs L, Brix TH (2013) Graves\u2019 disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study. Thyroid 23(4):408\u2013413. https:\/\/doi.org\/10.1089\/thy.2012.0500","journal-title":"Thyroid"},{"issue":"1","key":"2653_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-16-0576","volume":"176","author":"OM Dekkers","year":"2017","unstructured":"Dekkers OM, Horv\u00e1th-Puh\u00f3 E, Cannegieter SC, Vandenbroucke JP, S\u00f8rensen HT, J\u00f8rgensen JO (2017) Acute cardiovascular events and all-cause mortality in patients with hyperthyroidism: a population-based cohort study. Eur J Endocrinol 176(1):1\u20139. https:\/\/doi.org\/10.1530\/EJE-16-0576","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2653_CR26","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1210\/jc.2017-00166","volume":"102","author":"M Lillevang-Johansen","year":"2017","unstructured":"Lillevang-Johansen M, Abrahamsen B, J\u00f8rgensen HL, Brix TH, Heged\u00fcs L (2017) Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH. J Clin Endocrinol Metab 102(7):2301\u20132309. https:\/\/doi.org\/10.1210\/jc.2017-00166","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2653_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1530\/EJE-16-0954","volume":"176","author":"CF Schwensen","year":"2017","unstructured":"Schwensen CF, Brandt F, Heged\u00fcs L, Brix TH (2017) Mortality in graves\u2019 orbitopathy is increased and influenced by gender, age and pre-existing morbidity: a nationwide Danish register study. Eur J Endocrinol 176(6):669\u2013676. https:\/\/doi.org\/10.1530\/EJE-16-0954","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2653_CR28","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1089\/thy.2019.0543","volume":"30","author":"HJ Kim","year":"2020","unstructured":"Kim HJ, Kang T, Kang MJ, Ahn HS, Sohn SY (2020) Incidence and mortality of myocardial infarction and stroke in patients with hyperthyroidism: a nationwide cohort study in Korea. Thyroid 30(7):955\u2013965. https:\/\/doi.org\/10.1089\/thy.2019.0543","journal-title":"Thyroid"},{"issue":"5","key":"2653_CR29","doi-asserted-by":"publisher","first-page":"e250066","DOI":"10.1530\/EC-25-0066","volume":"14","author":"Q Chen","year":"2025","unstructured":"Chen Q, Chen D, Wang X, Zheng Y, Zhang L, Li Z et al (2025) Increased risk of multisystem comorbidities and disease trajectories following hyperthyroidism: evidence from the 0.5 million UK biobank population. Endocr Connect 14(5):e250066. https:\/\/doi.org\/10.1530\/EC-25-0066","journal-title":"Endocr Connect"},{"issue":"11","key":"2653_CR30","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1056\/NEJM199803123381103","volume":"338","author":"JA Franklyn","year":"1998","unstructured":"Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P (1998) Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 338(11):712\u2013718. https:\/\/doi.org\/10.1056\/NEJM199803123381103","journal-title":"N Engl J Med"},{"issue":"1","key":"2653_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.294.1.71","volume":"294","author":"JA Franklyn","year":"2005","unstructured":"Franklyn JA, Sheppard MC, Maisonneuve P (2005) Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 294(1):71\u201380. https:\/\/doi.org\/10.1001\/jama.294.1.71","journal-title":"JAMA"},{"issue":"9","key":"2653_CR32","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1089\/thy.2017.0461","volume":"28","author":"E Ry\u00f6di","year":"2018","unstructured":"Ry\u00f6di E, Metso S, Huhtala H, V\u00e4lim\u00e4ki M, Auvinen A, Jaatinen P (2018) Cardiovascular morbidity and mortality after treatment of hyperthyroidism with either radioactive iodine or thyroidectomy. Thyroid 28(9):1111\u20131120. https:\/\/doi.org\/10.1089\/thy.2017.0461","journal-title":"Thyroid"},{"issue":"5","key":"2653_CR33","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1210\/jc.2012-3459","volume":"98","author":"K Boelaert","year":"2013","unstructured":"Boelaert K, Maisonneuve P, Torlinska B, Franklyn JA (2013) Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab 98(5):1869\u20131882. https:\/\/doi.org\/10.1210\/jc.2012-3459","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2653_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/bjs.10665","volume":"105","author":"P Giesecke","year":"2018","unstructured":"Giesecke P, Frykman V, Wallin G, L\u00f6nn S, Discacciati A, T\u00f6rring O, Rosenqvist M (2018) All-cause and cardiovascular mortality risk after surgery versus radioiodine treatment for hyperthyroidism. Br J Surg 105(3):279\u2013286. https:\/\/doi.org\/10.1002\/bjs.10665","journal-title":"Br J Surg"},{"issue":"4","key":"2653_CR35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/bjs\/znab474","volume":"109","author":"X Liu","year":"2022","unstructured":"Liu X, Wong CKH, Chan WWL, Tang EHM, Woo YC, Liu SYW et al (2022) Long-term outcome of patients treated with antithyroid drugs, radioactive iodine or surgery for persistent or relapsed graves\u2019 disease. Br J Surg 109(4):381\u2013389. https:\/\/doi.org\/10.1093\/bjs\/znab474","journal-title":"Br J Surg"},{"key":"2653_CR36","doi-asserted-by":"publisher","first-page":"761782","DOI":"10.3389\/fendo.2021.761782","volume":"12","author":"E Song","year":"2021","unstructured":"Song E, Kim M, Park S, Park MJ, Kim JA, Roh E et al (2021) Treatment modality and risk of heart failure in patients with long-standing graves\u2019 disease: a nationwide population-based cohort study. Front Endocrinol (Lausanne) 12:761782. https:\/\/doi.org\/10.3389\/fendo.2021.761782","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2653_CR37","doi-asserted-by":"publisher","first-page":"1032764","DOI":"10.3389\/fendo.2022.1032764","volume":"13","author":"YY Cho","year":"2022","unstructured":"Cho YY, Kim B, Choi D, Kim CH, Shin DW, Kim JS et al (2022) Graves\u2019 disease, its treatments, and the risk of atrial fibrillation: A Korean population-based study. Front Endocrinol (Lausanne) 13:1032764. https:\/\/doi.org\/10.3389\/fendo.2022.1032764","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2653_CR38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.mayocp.2022.12.013","volume":"98","author":"JA Naser","year":"2023","unstructured":"Naser JA, Pislaru SV, Stan MN, Lin G (2023) Incidence, risk factors, and outcomes of incident atrial fibrillation in patients with graves disease. Mayo Clin Proc 98(6):883\u2013891. https:\/\/doi.org\/10.1016\/j.mayocp.2022.12.013","journal-title":"Mayo Clin Proc"},{"key":"2653_CR39","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.2147\/IJGM.S484910","volume":"17","author":"Y Guo","year":"2024","unstructured":"Guo Y, Huang D, Sun J, Zhai Z, Xiao H, Hao W et al (2024) Radioactive iodine-131 therapy reduced the risk of maces and all-cause mortality in elderly with hyperthyroidism combined with type 2 diabetes. Int J Gen Med 17:4281\u20134295. https:\/\/doi.org\/10.2147\/IJGM.S484910","journal-title":"Int J Gen Med"},{"issue":"2","key":"2653_CR40","doi-asserted-by":"publisher","first-page":"e240393","DOI":"10.1530\/ETJ-24-0393","volume":"14","author":"K Elomaa","year":"2025","unstructured":"Elomaa K, Spick M, Gan EH, Pearce SH, Geifman N (2025) Variable hyperthyroidism outcomes related to different treatment regimens: an analysis of UK biobank data. Eur Thyroid J 14(2):e240393. https:\/\/doi.org\/10.1530\/ETJ-24-0393","journal-title":"Eur Thyroid J"},{"issue":"3","key":"2653_CR41","doi-asserted-by":"publisher","first-page":"e240904","DOI":"10.1001\/jamanetworkopen.2024.0904","volume":"7","author":"CC Peng","year":"2024","unstructured":"Peng CC, Lin YJ, Lee SY, Lin SM, Han C, Loh CH et al (2024) MACE and hyperthyroidism treated with medication, radioactive iodine, or thyroidectomy. JAMA Netw Open 7(3):e240904. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.0904","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2653_CR42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/S2213-8587(19)30059-2","volume":"7","author":"OE Okosieme","year":"2019","unstructured":"Okosieme OE, Taylor PN, Evans C, Thayer D, Chai A, Khan I et al (2019) Primary therapy of graves\u2019 disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol 7(4):278\u2013287. https:\/\/doi.org\/10.1016\/S2213-8587(19)30059-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2653_CR43","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1210\/jcem.87.3.8333","volume":"87","author":"EK Alexander","year":"2002","unstructured":"Alexander EK, Larsen PR (2002) High dose of (131)I therapy for the treatment of hyperthyroidism caused by graves\u2019 disease. J Clin Endocrinol Metab 87(3):1073\u20131077. https:\/\/doi.org\/10.1210\/jcem.87.3.8333","journal-title":"J Clin Endocrinol Metab"},{"issue":"1\u20132","key":"2653_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.mce.2009.08.028","volume":"313","author":"E Kress","year":"2009","unstructured":"Kress E, Samarut J, Plateroti M (2009) Thyroid hormones and the control of cell proliferation or cell differentiation: paradox or duality? Mol Cell Endocrinol 313(1\u20132):36\u201349. https:\/\/doi.org\/10.1016\/j.mce.2009.08.028","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"2653_CR45","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1530\/ERC-12-0219","volume":"20","author":"LC Moeller","year":"2013","unstructured":"Moeller LC, F\u00fchrer D (2013) Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. Endocr Relat Cancer 20(2):R19\u2013R29. https:\/\/doi.org\/10.1530\/ERC-12-0219","journal-title":"Endocr Relat Cancer"},{"issue":"17","key":"2653_CR46","doi-asserted-by":"publisher","first-page":"14735","DOI":"10.18632\/oncotarget.4023","volume":"6","author":"HY Lin","year":"2015","unstructured":"Lin HY, Glinsky GV, Mousa SA, Davis PJ (2015) Thyroid hormone and anti-apoptosis in tumor cells. Oncotarget 6(17):14735\u201314743. https:\/\/doi.org\/10.18632\/oncotarget.4023","journal-title":"Oncotarget"},{"key":"2653_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.steroids.2016.05.006","volume":"114","author":"HY Lin","year":"2016","unstructured":"Lin HY, Chin YT, Nana AW, Shih YJ, Lai HY, Tang HY et al (2016) Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells. Steroids 114:59\u201367. https:\/\/doi.org\/10.1016\/j.steroids.2016.05.006","journal-title":"Steroids"},{"issue":"1","key":"2653_CR48","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0303-7207(95)03490-x","volume":"109","author":"M Esquenet","year":"1995","unstructured":"Esquenet M, Swinnen JV, Heyns W, Verhoeven G (1995) Triiodothyronine modulates growth, secretory function and androgen receptor concentration in the prostatic carcinoma cell line LNCaP. Mol Cell Endocrinol 109(1):105\u2013111. https:\/\/doi.org\/10.1016\/0303-7207(95)03490-x","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"2653_CR49","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.onc.1205136","volume":"21","author":"S Dinda","year":"2002","unstructured":"Dinda S, Sanchez A, Moudgil V (2002) Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene 21(5):761\u2013768. https:\/\/doi.org\/10.1038\/sj.onc.1205136","journal-title":"Oncogene"},{"issue":"2","key":"2653_CR50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s0304-3835(02)00614-6","volume":"192","author":"JM Gonz\u00e1lez-Sancho","year":"2003","unstructured":"Gonz\u00e1lez-Sancho JM, Garc\u00eda V, Bonilla F, Mu\u00f1oz A (2003) Thyroid hormone receptors\/thr genes in human cancer. Cancer Lett 192(2):121\u2013132. https:\/\/doi.org\/10.1016\/s0304-3835(02)00614-6","journal-title":"Cancer Lett"},{"issue":"1\u20132","key":"2653_CR51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jsbmb.2007.12.008","volume":"109","author":"LC Hall","year":"2008","unstructured":"Hall LC, Salazar EP, Kane SR, Liu N (2008) Effects of thyroid hormones on human breast cancer cell proliferation. J Steroid Biochem Mol Biol 109(1\u20132):57\u201366. https:\/\/doi.org\/10.1016\/j.jsbmb.2007.12.008","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"7","key":"2653_CR52","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.tem.2009.03.011","volume":"20","author":"A Aranda","year":"2009","unstructured":"Aranda A, Mart\u00ednez-Iglesias O, Ruiz-Llorente L, Garc\u00eda-Carpizo V, Zambrano A (2009) Thyroid receptor: roles in cancer. Trends Endocrinol Metab 20(7):318\u2013324. https:\/\/doi.org\/10.1016\/j.tem.2009.03.011","journal-title":"Trends Endocrinol Metab"},{"issue":"12","key":"2653_CR53","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJM198803243181206","volume":"318","author":"S Filetti","year":"1988","unstructured":"Filetti S, Belfiore A, Amir SM, Daniels GH, Ippolito O, Vigneri R, Ingbar SH (1988) The role of thyroid-stimulating antibodies of graves\u2019 disease in differentiated thyroid cancer. N Engl J Med 318(12):753\u2013759. https:\/\/doi.org\/10.1056\/NEJM198803243181206","journal-title":"N Engl J Med"},{"issue":"1","key":"2653_CR54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1756-6614-6-8","volume":"6","author":"P Szychta","year":"2013","unstructured":"Szychta P, Szychta W, Gesing A, Lewi\u0144ski A, Karbownik-Lewi\u0144ska M (2013) TSH receptor antibodies have predictive value for breast cancer - retrospective analysis. Thyroid Res 6(1):8. https:\/\/doi.org\/10.1186\/1756-6614-6-8","journal-title":"Thyroid Res"},{"issue":"2","key":"2653_CR55","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1158\/1055-9965.EPI-08-0911","volume":"18","author":"AI Hellevik","year":"2009","unstructured":"Hellevik AI, Asvold BO, Bj\u00f8ro T, Romundstad PR, Nilsen TI, Vatten LJ (2009) Thyroid function and cancer risk: a prospective population study. Cancer Epidemiol Biomarkers Prev 18(2):570\u2013574. https:\/\/doi.org\/10.1158\/1055-9965.EPI-08-0911","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"2653_CR56","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/sj.bjc.6605624","volume":"102","author":"X Shu","year":"2010","unstructured":"Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K (2010) Cancer risk in patients hospitalised for graves\u2019 disease: a population-based cohort study in Sweden. Br J Cancer 102(9):1397\u20131399. https:\/\/doi.org\/10.1038\/sj.bjc.6605624","journal-title":"Br J Cancer"},{"issue":"7","key":"2653_CR57","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1089\/thy.2012.0568","volume":"23","author":"YK Chen","year":"2013","unstructured":"Chen YK, Lin CL, Chang YJ, Cheng FT, Peng CL, Sung FC et al (2013) Cancer risk in patients with graves\u2019 disease: a nationwide cohort study. Thyroid 23(7):879\u2013884. https:\/\/doi.org\/10.1089\/thy.2012.0568","journal-title":"Thyroid"},{"issue":"4","key":"2653_CR58","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1530\/EJE-15-0989","volume":"174","author":"M S\u00f8gaard","year":"2016","unstructured":"S\u00f8gaard M, Farkas DK, Ehrenstein V, J\u00f8rgensen JO, Dekkers OM, S\u00f8rensen HT (2016) Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study. Eur J Endocrinol 174(4):409\u2013414. https:\/\/doi.org\/10.1530\/EJE-15-0989","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2653_CR59","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1210\/jc.2016-2104","volume":"101","author":"SR Khan","year":"2016","unstructured":"Khan SR, Chaker L, Ruiter R, Aerts JG, Hofman A, Dehghan A et al (2016) Thyroid function and cancer risk: the Rotterdam study. J Clin Endocrinol Metab 101(12):5030\u20135036. https:\/\/doi.org\/10.1210\/jc.2016-2104","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2653_CR60","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1089\/thy.2017.0063","volume":"27","author":"NMY Journy","year":"2017","unstructured":"Journy NMY, Bernier MO, Doody MM, Alexander BH, Linet MS, Kitahara CM (2017) Hyperthyroidism, hypothyroidism, and Cause-Specific mortality in a large cohort of women. Thyroid 27(8):1001\u20131010. https:\/\/doi.org\/10.1089\/thy.2017.0063","journal-title":"Thyroid"},{"issue":"4","key":"2653_CR61","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1530\/ERC-19-0417","volume":"27","author":"TV Tran","year":"2020","unstructured":"Tran TV, Kitahara CM, de Vathaire F, Boutron-Ruault MC, Journy N (2020) Thyroid dysfunction and cancer incidence: a systematic review and meta-analysis. Endocr Relat Cancer 27(4):245\u2013259. https:\/\/doi.org\/10.1530\/ERC-19-0417","journal-title":"Endocr Relat Cancer"},{"key":"2653_CR62","doi-asserted-by":"publisher","first-page":"984593","DOI":"10.3389\/fendo.2022.984593","volume":"13","author":"M Han","year":"2022","unstructured":"Han M, Wang Y, Jin Y, Zhao X, Cui H, Wang G, Gang X (2022) Benign thyroid disease and the risk of breast cancer: an updated systematic review and meta-analysis. Front Endocrinol (Lausanne) 13:984593. https:\/\/doi.org\/10.3389\/fendo.2022.984593","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2653_CR63","doi-asserted-by":"publisher","first-page":"e230181","DOI":"10.1530\/ETJ-23-0181","volume":"13","author":"T Riis","year":"2024","unstructured":"Riis T, Bonnema SJ, Brix TH, Folkestad L (2024) Hyperthyroidism and the risk of non-thyroid cancer: a Danish register-based long-term follow-up study. Eur Thyroid J 13(2):e230181. https:\/\/doi.org\/10.1530\/ETJ-23-0181","journal-title":"Eur Thyroid J"},{"key":"2653_CR64","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijsu.2015.11.027","volume":"27","author":"JUL Staniforth","year":"2016","unstructured":"Staniforth JUL, Erdirimanne S, Eslick GD (2016) Thyroid carcinoma in graves\u2019 disease: A meta-analysis. Int J Surg 27:118\u2013125. https:\/\/doi.org\/10.1016\/j.ijsu.2015.11.027","journal-title":"Int J Surg"},{"key":"2653_CR65","doi-asserted-by":"publisher","unstructured":"Palella M, Giustolisi FM, Modica Fiascaro A, Fichera M, Palmieri A et al (20239) Risk and prognosis of thyroid cancer in patients with Graves\u2019 disease: an umbrella review. Cancers (Basel) 15(10):2724. https:\/\/doi.org\/10.3390\/cancers15102724","DOI":"10.3390\/cancers15102724"},{"issue":"4","key":"2653_CR66","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1210\/jcem-70-4-830","volume":"70","author":"A Belfiore","year":"1990","unstructured":"Belfiore A, Garofalo MR, Giuffrida D, Runello F, Filetti S, Fiumara A et al (1990) Increased aggressiveness of thyroid cancer in patients with graves\u2019 disease. J Clin Endocrinol Metab 70(4):830\u2013835. https:\/\/doi.org\/10.1210\/jcem-70-4-830","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2653_CR67","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1210\/jcem.83.8.4997","volume":"83","author":"G Pellegriti","year":"1998","unstructured":"Pellegriti G, Belfiore A, Giuffrida D, Lupo L, Vigneri R (1998) Outcome of differentiated thyroid cancer in graves\u2019 patients. J Clin Endocrinol Metab 83(8):2805\u20132809. https:\/\/doi.org\/10.1210\/jcem.83.8.4997","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2653_CR68","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1210\/jc.2012-2843","volume":"98","author":"G Pellegriti","year":"2013","unstructured":"Pellegriti G, Mannarino C, Russo M, Terranova R, Marturano I, Vigneri R, Belfiore A (2013) Increased mortality in patients with differentiated thyroid cancer associated with graves\u2019 disease. J Clin Endocrinol Metab 98(3):1014\u20131021. https:\/\/doi.org\/10.1210\/jc.2012-2843","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2653_CR69","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40618-019-01088-5","volume":"3","author":"P Premoli","year":"2020","unstructured":"Premoli P, Tanda ML, Piantanida E, Veronesi G, Gallo D, Masiello E et al (2020) Features and outcome of differentiated thyroid carcinoma associated with graves\u2019 disease: results of a large, retrospective, multicenter study. J Endocrinol Invest 3(1):109\u2013116. https:\/\/doi.org\/10.1007\/s40618-019-01088-5","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"2653_CR70","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1089\/thy.2024.0178","volume":"34","author":"JY Lee","year":"2024","unstructured":"Lee JY, Lee MK, Lee JH, Kim K, Bae K, Sohn SY (2024) Cancer risks of patients with graves\u2019 disease who received antithyroid drugs as initial treatment: a nationwide population-based analysis. Thyroid 34(10):1271\u20131279. https:\/\/doi.org\/10.1089\/thy.2024.0178","journal-title":"Thyroid"},{"issue":"9","key":"2653_CR71","doi-asserted-by":"publisher","first-page":"e2126361","DOI":"10.1001\/jamanetworkopen.2021.26361","volume":"4","author":"B Biondi","year":"2021","unstructured":"Biondi B (2021) Radioactive iodine treatment in hyperthyroidism and cancer mortality - a still controversial issue. JAMA Netw Open 4(9):e2126361. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.26361","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2653_CR72","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1210\/clinem\/dgab700","volume":"107","author":"BW Kim","year":"2022","unstructured":"Kim BW (2022) Does radioactive iodine therapy for hyperthyroidism cause cancer? J Clin Endocrinol Metab 107(2):e448\u2013e457. https:\/\/doi.org\/10.1210\/clinem\/dgab700","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2653_CR73","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1210\/jcem-38-6-976","volume":"38","author":"BM Dobyns","year":"1974","unstructured":"Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV (1974) Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 38(6):976\u2013998. https:\/\/doi.org\/10.1210\/jcem-38-6-976","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2653_CR74","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jama.1968.03140380059014","volume":"205","author":"EL Saenger","year":"1968","unstructured":"Saenger EL, Thoma GE, Tompkins EA (1968) Incidence of leukemia following treatment of hyperthyroidism. Preliminary report of the cooperative thyrotoxicosis therapy Follow-Up study. JAMA 205(12):855\u2013862 PMID: 5695509","journal-title":"JAMA"},{"issue":"3","key":"2653_CR75","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/ije\/11.3.218","volume":"11","author":"DA Hoffman","year":"1982","unstructured":"Hoffman DA, McConahey WM, Fraumeni JF Jr, Kurland LT (1982) Cancer incidence following treatment of hyperthyroidism. Int J Epidemiol 11(3):218\u2013224. https:\/\/doi.org\/10.1093\/ije\/11.3.218","journal-title":"Int J Epidemiol"},{"issue":"5","key":"2653_CR76","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/oxfordjournals.aje.a114900","volume":"127","author":"MB Goldman","year":"1988","unstructured":"Goldman MB, Maloof F, Monson RR, Aschengrau A, Cooper DS, Ridgway EC (1988) Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women. Am J Epidemiol 127(5):969\u2013980. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a114900","journal-title":"Am J Epidemiol"},{"issue":"6","key":"2653_CR77","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/ijc.2910500611","volume":"50","author":"P Hall","year":"1992","unstructured":"Hall P, Berg G, Bjelkengren G, Boice JD Jr, Ericsson UB, Hallquist A et al (1992) Cancer mortality after iodine-131 therapy for hyperthyroidism. Int J Cancer 50(6):886\u2013890. https:\/\/doi.org\/10.1002\/ijc.2910500611","journal-title":"Int J Cancer"},{"issue":"4","key":"2653_CR78","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jama.280.4.347","volume":"280","author":"E Ron","year":"1998","unstructured":"Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB et al (1998) Cancer mortality following treatment for adult hyperthyroidism. Cooperative thyrotoxicosis therapy Follow-up study group. JAMA 280(4):347\u2013355. https:\/\/doi.org\/10.1001\/jama.280.4.347","journal-title":"JAMA"},{"issue":"9170","key":"2653_CR79","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/S0140-6736(98)12295-X","volume":"353","author":"JA Franklyn","year":"1999","unstructured":"Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P (1999) Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353(9170):2111\u20132115. https:\/\/doi.org\/10.1016\/S0140-6736(98)12295-X","journal-title":"Lancet"},{"issue":"10","key":"2653_CR80","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/cncr.22635","volume":"109","author":"S Metso","year":"2007","unstructured":"Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P (2007) Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 109(10):1972\u20131979. https:\/\/doi.org\/10.1002\/cncr.22635","journal-title":"Cancer"},{"issue":"10","key":"2653_CR81","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1210\/jc.2015-1874","volume":"100","author":"E Ry\u00f6di","year":"2015","unstructured":"Ry\u00f6di E, Metso S, Jaatinen P, Huhtala H, Saaristo R, V\u00e4lim\u00e4ki M, Auvinen A (2015) Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism. J Clin Endocrinol Metab 100(10):3710\u20133717. https:\/\/doi.org\/10.1210\/jc.2015-1874","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2653_CR82","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1001\/jamainternmed.2019.0981","volume":"179","author":"CM Kitahara","year":"2019","unstructured":"Kitahara CM, Berrington de Gonzalez A, Bouville A, Brill AB, Doody MM, Melo DR et al (2019) Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism. JAMA Intern Med 179(8):1034\u20131042. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0981","journal-title":"JAMA Intern Med"},{"issue":"4","key":"2653_CR83","doi-asserted-by":"publisher","first-page":"dgz305","DOI":"10.1210\/clinem\/dgz305","volume":"105","author":"E Hindi\u00e9","year":"2020","unstructured":"Hindi\u00e9 E, Ain KB, Zerdoud S, Avram AM (2020) Association of radioactive iodine treatment of hyperthyroidism with cancer mortality: an unjustified warning? J Clin Endocrinol Metab 105(4):dgz305. https:\/\/doi.org\/10.1210\/clinem\/dgz305","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2653_CR84","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.2967\/jnumed.119.235929","volume":"60","author":"BS Greenspan","year":"2019","unstructured":"Greenspan BS, Siegel JA, Hassan A, Silberstein EB (2019) There is no association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism. J Nucl Med 60(11):1500\u20131501. https:\/\/doi.org\/10.2967\/jnumed.119.235929","journal-title":"J Nucl Med"},{"issue":"10","key":"2653_CR85","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/RLU.0000000000002792","volume":"44","author":"M Tulchinsky","year":"2019","unstructured":"Tulchinsky M, Brill AB (2019) Spotlight on the association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism is keeping the highest risk from antithyroid drugs in the blind spot. Clin Nucl Med 44(10):789\u2013791. https:\/\/doi.org\/10.1097\/RLU.0000000000002792","journal-title":"Clin Nucl Med"},{"issue":"7","key":"2653_CR86","doi-asserted-by":"publisher","first-page":"e209660","DOI":"10.1001\/jamanetworkopen.2020.9660","volume":"3","author":"CM Kitahara","year":"2020","unstructured":"Kitahara CM, Preston DL, Sosa JA, Berrington de Gonzalez A (2020) Association of radioactive iodine, antithyroid drug, and surgical treatments with solid cancer mortality in patients with hyperthyroidism. JAMA Netw Open 3(7):e209660. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.9660","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2653_CR87","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/thy.2019.0205","volume":"30","author":"N Gronich","year":"2020","unstructured":"Gronich N, Lavi I, Rennert G, Saliba W (2020) Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study. Thyroid 30(2):243\u2013250. https:\/\/doi.org\/10.1089\/thy.2019.0205","journal-title":"Thyroid"},{"issue":"4","key":"2653_CR88","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.eprac.2020.10.018","volume":"27","author":"D Yan","year":"2021","unstructured":"Yan D, Chen C, Yan H, Liut T, Yan H, Yuan J (2021) Mortality risk after radioiodine therapy for hyperthyroidism: a systematic review and meta-analysis. Endocr Pract 27(4):362\u2013369. https:\/\/doi.org\/10.1016\/j.eprac.2020.10.018","journal-title":"Endocr Pract"},{"issue":"9","key":"2653_CR89","doi-asserted-by":"publisher","first-page":"e2125072","DOI":"10.1001\/jamanetworkopen.2021.25072","volume":"4","author":"SR Shim","year":"2021","unstructured":"Shim SR, Kitahara CM, Cha ES, Kim SJ, Bang YJ, Lee WJ (2021) Cancer risk after radioactive iodine treatment for hyperthyroidism: a systematic review and meta-analysis. JAMA Netw Open 4(9):e2125072. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.25072","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2653_CR90","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1159\/000517174","volume":"10","author":"SL Lutterman","year":"2021","unstructured":"Lutterman SL, Zwaveling-Soonawala N, Verberne HJ, Verburg FA, van Trotsenburg ASP, Mooij CF (2021) The efficacy and short- and long-term side effects of radioactive iodine treatment in pediatric graves\u2019 disease: a systematic review. Eur Thyroid J 10(5):353\u2013363. https:\/\/doi.org\/10.1159\/000517174","journal-title":"Eur Thyroid J"},{"issue":"5","key":"2653_CR91","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2967\/jnumed.123.266531","volume":"65","author":"KJ Kim","year":"2024","unstructured":"Kim KJ, Choi J, Kim KJ, Song E, Yu JH, Kim NH et al (2024) Cancer risk in graves disease with radioactive 131I treatment: a nationwide cohort study. J Nucl Med 65(5):693\u2013699. https:\/\/doi.org\/10.2967\/jnumed.123.266531","journal-title":"J Nucl Med"},{"key":"2653_CR92","doi-asserted-by":"publisher","first-page":"dgaf231","DOI":"10.1210\/clinem\/dgaf231","volume":"11","author":"S Hiruma","year":"2025","unstructured":"Hiruma S, Watanabe N, Noh JY, Hirose R, Koshibu M, Ichikawa M et al (2025) Occurrence of newly diagnosed thyroid cancer is not increased after radioactive iodine therapy for graves\u2019 disease. J Clin Endocrinol Metab 2025 Apr 11:dgaf231. https:\/\/doi.org\/10.1210\/clinem\/dgaf231Online ahead of print","journal-title":"J Clin Endocrinol Metab 2025 Apr"},{"issue":"3","key":"2653_CR93","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/cen.14136","volume":"92","author":"PN Taylor","year":"2020","unstructured":"Taylor PN, Okosieme OE, Chatterjee K, Boelaert K, Executive Committees of the Society for Endocrinology and the British Thyroid Association (2020) Joint statement from the society for endocrinology and the British thyroid association regarding \u2018association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism\u2019. Clin Endocrinol (Oxf) 92(3):266\u2013267. https:\/\/doi.org\/10.1111\/cen.14136","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2653_CR94","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1007\/s00259-023-06274-5","volume":"50","author":"A Campenn\u00ec","year":"2023","unstructured":"Campenn\u00ec A, Avram AM, Verburg FA, Iakovou I, H\u00e4nscheid H, de Keizer B et al (2023) The EANM guideline on radioiodine therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging 50(11):3324\u20133348. https:\/\/doi.org\/10.1007\/s00259-023-06274-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2653_CR95","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000490384","volume":"7","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Bartalena L, Heged\u00fcs L, Leenhardt L, Poppe K, Pearce SH (2018) 2018 European thyroid association guideline for the management of graves\u2019 hyperthyroidism. Eur Thyroid J 7(4):167\u2013186. https:\/\/doi.org\/10.1159\/000490384","journal-title":"Eur Thyroid J"},{"issue":"10","key":"2653_CR96","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMcp0806317","volume":"360","author":"L Bartalena","year":"2009","unstructured":"Bartalena L, Tanda ML (2009) Graves\u2019 ophthalmopathy. N Engl J Med 360(10):994\u20131001. https:\/\/doi.org\/10.1056\/NEJMcp0806317","journal-title":"N Engl J Med"},{"issue":"4","key":"2653_CR97","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1210\/jc.2012-3873","volume":"98","author":"ML Tanda","year":"2013","unstructured":"Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L et al (2013) Prevalence and natural history of graves\u2019 orbitopathy in a large series of patients with newly diagnosed graves\u2019 hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98(4):1443\u20131449. https:\/\/doi.org\/10.1210\/jc.2012-3873","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2653_CR98","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s40618-020-01479-z","volume":"44","author":"S Ippolito","year":"2021","unstructured":"Ippolito S, Cusini C, Lasalvia P, Gianfagna F, Veronesi G, Gallo D et al (2021) Change in newly diagnosed graves\u2019 disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression. J Endocrinol Invest 44(8):1707\u20131718. https:\/\/doi.org\/10.1007\/s40618-020-01479-z","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2653_CR99","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1089\/thy.2024.0304","volume":"34","author":"KN Rachmasari","year":"2024","unstructured":"Rachmasari KN, Hamadi D, Thapa P, Bradley EA, Stan MN (2024) Epidemiology and management of moderate to severe thyroid eye disease in the united states: analysis of a healthcare claims database. Thyroid 34(12):1522\u20131530. https:\/\/doi.org\/10.1089\/thy.2024.0304","journal-title":"Thyroid"},{"issue":"6S","key":"2653_CR100","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/IOP.0000000000002467","volume":"39","author":"L Bartalena","year":"2023","unstructured":"Bartalena L, Gallo D, Tanda ML, Kahaly GJ (2023) Thyroid eye disease: epidemiology, natural history, and risk factors. Ophthalmic Plast Reconstr Surg 39(6S):S2\u2013S8. https:\/\/doi.org\/10.1097\/IOP.0000000000002467","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"5","key":"2653_CR101","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/archinte.1990.00390170124027","volume":"150","author":"MF Prummel","year":"1990","unstructured":"Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R (1990) Effect of abnormal thyroid function on the severity of graves\u2019 ophthalmopathy. Arch Intern Med 150(5):1098\u20131101 PMID: 1691908","journal-title":"Arch Intern Med"},{"key":"2653_CR102","unstructured":"Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R (1989) Amelioration of eye changes of Graves\u2019 ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh) 121 (suppl 2): 185\u2013189"},{"issue":"9","key":"2653_CR103","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.1210\/jc.2005-0507","volume":"90","author":"P Perros","year":"2005","unstructured":"Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J (2005) A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 90(9):5321\u20133523. https:\/\/doi.org\/10.1210\/jc.2005-0507","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2653_CR104","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C et al (2021) The 2021 European group on graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves\u2019 orbitopathy. Eur J Endocrinol 185(4):G43\u2013G67. https:\/\/doi.org\/10.1530\/EJE-21-0479","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2653_CR105","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1089\/thy.2022.0251","volume":"32","author":"HB Burch","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM et al (2022) Management of thyroid eye disease: a consensus statement by the American thyroid association and the European thyroid association. Thyroid 32(12):1439\u20131470. https:\/\/doi.org\/10.1089\/thy.2022.0251","journal-title":"Thyroid"},{"issue":"26","key":"2653_CR106","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJM199206253262603","volume":"326","author":"L Tallstedt","year":"1992","unstructured":"Tallstedt L, Lundell G, T\u00f8rring O, Wallin G, Ljunggren JG, Blomgren H, Taube A (1992) Occurrence of ophthalmopathy after treatment for graves\u2019 hyperthyroidism. The thyroid study group. N Engl J Med 326(26):1733\u20131173. https:\/\/doi.org\/10.1056\/NEJM199206253262603","journal-title":"N Engl J Med"},{"issue":"4","key":"2653_CR107","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1046\/j.1365-2265.1999.00843.x","volume":"51","author":"C Marcocci","year":"1999","unstructured":"Marcocci C, Bruno-Bossio G, Manetti L, Tanda ML, Miccoli P, Iacconi P et al (1999) The course of graves\u2019 ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf) 51(4):503\u2013508. https:\/\/doi.org\/10.1046\/j.1365-2265.1999.00843.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"20","key":"2653_CR108","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM198911163212001","volume":"321","author":"L Bartalena","year":"1989","unstructured":"Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A (1989) Use of corticosteroids to prevent progression of graves\u2019 ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 321(20):1349\u20131352. https:\/\/doi.org\/10.1056\/NEJM198911163212001","journal-title":"N Engl J Med"},{"issue":"10","key":"2653_CR109","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1210\/jc.2009-0747","volume":"94","author":"F Tr\u00e4isk","year":"2009","unstructured":"Tr\u00e4isk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J et al (2009) Thyroid-associated ophthalmopathy after treatment for graves\u2019 hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94(10):3700\u20133707. https:\/\/doi.org\/10.1210\/jc.2009-0747","journal-title":"J Clin Endocrinol Metab"},{"issue":"1064","key":"2653_CR110","doi-asserted-by":"publisher","first-page":"20160418","DOI":"10.1259\/bjr.20160418","volume":"89","author":"J Wang","year":"2016","unstructured":"Wang J, Qin L (2016) Radioiodine therapy versus antithyroid drugs in graves\u2019 disease: a meta-analysis of randomized controlled trials. Br J Radiol 89(1064):20160418. https:\/\/doi.org\/10.1259\/bjr.20160418","journal-title":"Br J Radiol"},{"issue":"2","key":"2653_CR111","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM199801083380201","volume":"338","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell\u2019Unto E et al (1998) Relation between therapy for hyperthyroidism and the course of graves\u2019 ophthalmopathy. N Engl J Med 338(2):73\u201378. https:\/\/doi.org\/10.1056\/NEJM199801083380201","journal-title":"N Engl J Med"},{"issue":"3","key":"2653_CR112","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1210\/jc.2009-2130","volume":"95","author":"A Lai","year":"2010","unstructured":"Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E et al (2010) Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves\u2019 orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 95(3):1333\u20131337. https:\/\/doi.org\/10.1210\/jc.2009-2130","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2653_CR113","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1089\/thy.2014.0218","volume":"24","author":"S Shiber","year":"2014","unstructured":"Shiber S, Stiebel-Kalish H, Shimon I, Grossman A, Robenshtok E (2014) Glucocorticoid regimens for prevention of graves\u2019 ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis. Thyroid 24(10):1515\u20131523. https:\/\/doi.org\/10.1089\/thy.2014.0218","journal-title":"Thyroid"},{"issue":"7","key":"2653_CR114","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1210\/jc.2014-4542","volume":"100","author":"N Watanabe","year":"2015","unstructured":"Watanabe N, Noh JY, Kozaki A, Iwaku K, Sekiya K, Kosuga Y et al (2015) Radioiodine-associated exacerbation of graves\u2019 orbitopathy in the Japanese population: randomized prospective study. J Clin Endocrinol Metab 100(7):2700\u20132708. https:\/\/doi.org\/10.1210\/jc.2014-4542","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2653_CR115","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1210\/clinem\/dgaf009","volume":"110","author":"L Bartalena","year":"2025","unstructured":"Bartalena L, Smith TJ (2025) Treatment of hyperthyroidism in graves\u2019 disease complicated by thyroid eye disease. J Clin Endocrinol Metab 110(4):922\u2013930. https:\/\/doi.org\/10.1210\/clinem\/dgaf009","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2653_CR116","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1210\/jcem.86.8.7737","volume":"86","author":"C Marcocci","year":"2001","unstructured":"Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell\u2019Unto E, Rocchi R et al (2001) Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86(8):3562\u20133567. https:\/\/doi.org\/10.1210\/jcem.86.8.7737","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2653_CR117","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1210\/jc.2006-1800","volume":"92","author":"F Menconi","year":"2007","unstructured":"Menconi F, Marin\u00f2 M, Pinchera A, Rocchi R, Mazzi B, Nardi M et al (2007) Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate graves\u2019 orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 92(5):1653\u20131658. https:\/\/doi.org\/10.1210\/jc.2006-1800","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2653_CR118","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1210\/jc.2013-3093","volume":"99","author":"M Moleti","year":"2014","unstructured":"Moleti M, Violi MA, Montanini D, Trombetta C, Di Bella B, Sturniolo G et al (2014) Radioiodine ablation of postsurgical thyroid remnants after treatment with Recombinant human TSH (rhTSH) in patients with moderate-to-severe graves\u2019 orbitopathy (GO): a prospective, randomized, single-blind clinical trial. J Clin Endocrinol Metab 99(5):1783\u20131789. https:\/\/doi.org\/10.1210\/jc.2013-3093","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2653_CR119","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1089\/thy.2024.0633","volume":"35","author":"G Cosentino","year":"2025","unstructured":"Cosentino G, Lanzolla G, Comi S, Maglionico MN, Posarelli C, Ciampa DA et al (2025) Ablative versus Conservative approach for hyperthyroidism treatment in patients with graves\u2019 orbitopathy: a retrospective cohort study. Thyroid 35(3):298\u2013306. https:\/\/doi.org\/10.1089\/thy.2024.0633","journal-title":"Thyroid"},{"issue":"3","key":"2653_CR120","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1089\/thy.2025.0059","volume":"35","author":"L Bartalena","year":"2025","unstructured":"Bartalena L, Tanda ML (2025) Is radioactive iodine contraindicated in patients with moderate-to-severe and active. Graves\u2019 Orbitopathy?? Thyroid 35(3):230\u2013231. https:\/\/doi.org\/10.1089\/thy.2025.0059","journal-title":"Graves\u2019 Orbitopathy?? Thyroid"},{"issue":"5","key":"2653_CR121","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1210\/er.2009-0041","volume":"31","author":"GE Krassas","year":"2010","unstructured":"Krassas GE, Poppe K, Glinoer D (2010) Thyroid function and human reproductive health. Endocr Rev 31(5):702\u2013755. https:\/\/doi.org\/10.1210\/er.2009-0041","journal-title":"Endocr Rev"},{"issue":"6","key":"2653_CR122","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/BF03346712","volume":"34","author":"A Oppo","year":"2011","unstructured":"Oppo A, Franceschi E, Atzeni F, Taberlet A, Mariotti S (2011) Effects of hyperthyroidism, hypothyroidism, and thyroid autoimmunity on female sexual function. J Endocrinol Invest 34(6):449\u2013534. https:\/\/doi.org\/10.1007\/BF03346712","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2653_CR123","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1530\/EJE-19-0903","volume":"182","author":"E Carosa","year":"2020","unstructured":"Carosa E, Sansone A, Jannini EA (2020) MANAGEMENT OF ENDOCRINE DISEASE: female sexual dysfunction for the endocrinologist. Eur J Endocrinol 182(6):R101\u2013R116. https:\/\/doi.org\/10.1530\/EJE-19-0903","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2653_CR124","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41443-023-00777-3","volume":"36","author":"A Cihan","year":"2024","unstructured":"Cihan A, Esen AA (2024) The impact of hyperthyroidism on sexual functions in men and women: a systematic review and meta-analysis. Int J Impot Res 36(4):339\u2013347. https:\/\/doi.org\/10.1038\/s41443-023-00777-3","journal-title":"Int J Impot Res"},{"issue":"8","key":"2653_CR125","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40618-016-0452-6","volume":"39","author":"G Mintziori","year":"2016","unstructured":"Mintziori G, Kita M, Duntas L, Goulis DG (2016) Consequences of hyperthyroidism in male and female fertility: pathophysiology and current management. J Endocrinol Invest 39(8):849\u2013853. https:\/\/doi.org\/10.1007\/s40618-016-0452-6","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"2653_CR126","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1089\/105072502320908330","volume":"12","author":"K Poppe","year":"2002","unstructured":"Poppe K, Glinoer D, Van Steirteghem A, Tournaye H, Devroey P, Schiettecatte J, Velkeniers B (2002) Thyroid dysfunction and autoimmunity in infertile women. Thyroid 12(11):997\u20131001. https:\/\/doi.org\/10.1089\/105072502320908330","journal-title":"Thyroid"},{"issue":"4","key":"2653_CR127","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1089\/thy.2019.0382","volume":"30","author":"C Dosiou","year":"2020","unstructured":"Dosiou C (2020) Thyroid and fertility: recent advances. Thyroid 30(4):479\u2013486. https:\/\/doi.org\/10.1089\/thy.2019.0382","journal-title":"Thyroid"},{"issue":"2\u20133","key":"2653_CR128","doi-asserted-by":"publisher","first-page":"J266","DOI":"10.1016\/j.jaut.2011.11.016","volume":"38","author":"HJA Carp","year":"2012","unstructured":"Carp HJA, Selmi C, Shoenfeld Y (2012) The autoimmune bases of infertility and pregnancy loss. J Autoimmun 38(2\u20133):J266\u2013J274. https:\/\/doi.org\/10.1016\/j.jaut.2011.11.016","journal-title":"J Autoimmun"},{"issue":"2\u20133","key":"2653_CR129","doi-asserted-by":"publisher","first-page":"J275","DOI":"10.1016\/j.jaut.2011.11.014","volume":"38","author":"G Twig","year":"2012","unstructured":"Twig G, Shina A, Amital H, Shoenfeld Y (2012) Pathogenesis of infertility and recurrent pregnancy loss in thyroid autoimmunity. J Autoimmun 38(2\u20133):J275\u2013J281. https:\/\/doi.org\/10.1016\/j.jaut.2011.11.014","journal-title":"J Autoimmun"},{"issue":"1","key":"2653_CR130","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12902-024-01817-9","volume":"24","author":"N Salari","year":"2024","unstructured":"Salari N, Heidarian P, Jalili F, Babajani F, Shohaimi S, Nasirian M, Mohammadi M (2024) The sexual dysfunction in women with thyroid disorders: a meta-analysis. BMC Endocr Disord 24(1):279. https:\/\/doi.org\/10.1186\/s12902-024-01817-9","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"2653_CR131","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/thy.2016.0457","volume":"27","author":"EK Alexander","year":"2017","unstructured":"Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C et al (2017) 2017 guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 27(3):315\u2013389. https:\/\/doi.org\/10.1089\/thy.2016.0457","journal-title":"Thyroid"},{"issue":"5","key":"2653_CR132","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1365-2605.2012.01266.x","volume":"35","author":"G Corona","year":"2012","unstructured":"Corona G, Wu FC, Forti G, Lee DM, O\u2019Connor DB, O\u2019Neill TW et al (2012) Thyroid hormones and male sexual function. Int J Androl 35(5):668\u2013679. https:\/\/doi.org\/10.1111\/j.1365-2605.2012.01266.x","journal-title":"Int J Androl"},{"issue":"9","key":"2653_CR133","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nrurol.2012.147","volume":"9","author":"G Corona","year":"2012","unstructured":"Corona G, Jannini EA, Vignozzi L, Rastrelli G, Maggi M (2012) The hormonal control of ejaculation. Nat Rev Urol 9(9):508\u2013519. https:\/\/doi.org\/10.1038\/nrurol.2012.147","journal-title":"Nat Rev Urol"},{"issue":"3","key":"2653_CR134","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12020-017-1303-8","volume":"58","author":"S La Vignera","year":"2017","unstructured":"La Vignera S, Vita R, Condorelli RA, Mongio\u00ec LM, Presti S, Benvenga S, Calogero AE (2017) Impact of thyroid disease on testicular function. Endocrine 58(3):397\u2013407. https:\/\/doi.org\/10.1007\/s12020-017-1303-8","journal-title":"Endocrine"},{"issue":"12","key":"2653_CR135","doi-asserted-by":"publisher","first-page":"6472","DOI":"10.1210\/jc.2005-1135","volume":"90","author":"C Carani","year":"2005","unstructured":"Carani C, Isidori AM, Granata A, Carosa E, Maggi M, Lenzi A, Jannini EA (2005) Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 90(12):6472\u20136479. https:\/\/doi.org\/10.1210\/jc.2005-1135","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2653_CR136","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1210\/jc.2007-2259","volume":"93","author":"GE Krassas","year":"2008","unstructured":"Krassas GE, Tziomalos K, Papadopoulou F, Pontikides N, Perros P (2008) Erectile dysfunction in patients with hyper- and hypothyroidism: how common and should we treat? J Clin Endocrinol Metab 93(5):1815\u20131819. https:\/\/doi.org\/10.1210\/jc.2007-2259","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2653_CR137","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/j.1365-2265.2007.03081.x","volume":"68","author":"AM Sawka","year":"2008","unstructured":"Sawka AM, Lea J, Alshehri B, Straus S, Tsang RW, Brierley JD et al (2008) A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol (Oxf) 68(4):610\u2013617. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.03081.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2653_CR138","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1530\/EJE-21-0315","volume":"185","author":"M Nies","year":"2021","unstructured":"Nies M, Arts EGJM, van Velsen EFS, Burgerhof JGM, Muller Kobold AC, Corssmit EPM et al (2021) Long-term male fertility after treatment with radioactive iodine for differentiated thyroid carcinoma. Eur J Endocrinol 185(6):775\u2013782. https:\/\/doi.org\/10.1530\/EJE-21-0315","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2653_CR139","first-page":"826","volume":"17","author":"JS Robertson","year":"1976","unstructured":"Robertson JS, Gorman CA (1976) Gonadal radiation dose and its genetic significance in radioiodine therapy of hyperthyroidism. J Nucl Med 17(9):826\u2013835 PMID: 956897","journal-title":"J Nucl Med"},{"issue":"9","key":"2653_CR140","first-page":"586","volume":"10","author":"P Starr","year":"1969","unstructured":"Starr P, Jaffe HL, Oettinger L Jr. (1969) Later results of 131-I treatment of hyperthyroidism in 73 children and adolescents: 1967 follow-up. J Nucl Med 10(9):586\u2013590 PMID: 5797846","journal-title":"J Nucl Med"},{"issue":"4","key":"2653_CR141","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1056\/NEJM197501232920401","volume":"292","author":"AM Safa","year":"1975","unstructured":"Safa AM, Schumacher OP, Rodriguez-Antunez A (1975) Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med 292(4):167\u2013171. https:\/\/doi.org\/10.1056\/NEJM197501232920401","journal-title":"N Engl J Med"},{"issue":"12","key":"2653_CR142","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1210\/clinem\/dgac573","volume":"107","author":"SA Rivkees","year":"2022","unstructured":"Rivkees SA (2022) Approach to the patient: management and the long-term consequences of graves\u2019 disease in children. J Clin Endocrinol Metab 107(12):3408\u20133417. https:\/\/doi.org\/10.1210\/clinem\/dgac573","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2653_CR143","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1365-2265.2006.02613.x","volume":"65","author":"C Ceccarelli","year":"2006","unstructured":"Ceccarelli C, Canale D, Battisti P, Caglieresi C, Moschini C, Fiore E et al (2006) Testicular function after 131I therapy for hyperthyroidism. Clin Endocrinol (Oxf) 65(4):446\u2013452. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02613.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2653_CR144","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1210\/jcem.87.8.8714","volume":"87","author":"GE Krassas","year":"2002","unstructured":"Krassas GE, Pontikides N, Deligianni V, Miras K (2002) A prospective controlled study of the impact of hyperthyroidism on reproductive function in males. J Clin Endocrinol Metab 87(8):3667\u20133671. https:\/\/doi.org\/10.1210\/jcem.87.8.8714","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2653_CR145","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1089\/thy.2005.15.1279","volume":"15","author":"M Abraham-Nordling","year":"2005","unstructured":"Abraham-Nordling M, T\u00f6rring O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J, Wallin G (2005) Graves\u2019 disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 15(11):1279\u20131286. https:\/\/doi.org\/10.1089\/thy.2005.15.1279","journal-title":"Thyroid"},{"issue":"4","key":"2653_CR146","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1530\/eje.1.02124","volume":"154","author":"T Watt","year":"2006","unstructured":"Watt T, Groenvold M, Rasmussen AK, Bonnema SJ, Heged\u00fcs L, Bjorner JB, Feldt-Rasmussen U (2006) Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol 154(4):501\u2013510. https:\/\/doi.org\/10.1530\/eje.1.02124","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2653_CR147","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1089\/thy.1998.8.653","volume":"8","author":"JG Ljunggren","year":"1998","unstructured":"Ljunggren JG, T\u00f6rring O, Wallin G, Taube A, Tallstedt L, Hamberger B, Lundell G (1998) Quality of life aspects and costs in treatment of graves\u2019 hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 8(8):653\u2013659. https:\/\/doi.org\/10.1089\/thy.1998.8.653","journal-title":"Thyroid"},{"issue":"5","key":"2653_CR148","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1530\/eje.0.1510549","volume":"151","author":"TV Elberling","year":"2004","unstructured":"Elberling TV, Rasmussen AK, Feldt-Rasmussen U, H\u00f8rding M, Perrild H, Waldemar G (2004) Impaired health-related quality of life in graves\u2019 disease. A prospective study. Eur J Endocrinol 151(5):549\u2013555. https:\/\/doi.org\/10.1530\/eje.0.1510549","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2653_CR149","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1089\/thy.1997.7.885","volume":"7","author":"MN Gerding","year":"1997","unstructured":"Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM (1997) Quality of life in patients with graves\u2019 ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid 7(6):885\u2013889. https:\/\/doi.org\/10.1089\/thy.1997.7.885","journal-title":"Thyroid"},{"issue":"3","key":"2653_CR150","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","volume":"54","author":"CB Terwee","year":"2001","unstructured":"Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R et al (2001) Interpretation and validity of changes in scores on the graves\u2019 ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf) 54(3):391\u2013398. https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01241.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2653_CR151","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1530\/eje.0.1460751","volume":"146","author":"C Terwee","year":"2002","unstructured":"Terwee C, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga W (2002) Long-term effects of graves\u2019 ophthalmopathy on health-related quality of life. Eur J Endocrinol 146(6):751\u2013757. https:\/\/doi.org\/10.1530\/eje.0.1460751","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2653_CR152","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2265.2005.02352.x","volume":"63","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT (2005) Psychosocial morbidity of graves\u2019 orbitopathy. Clin Endocrinol (Oxf) 63(4):395\u2013402. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02352.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"2653_CR153","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1210\/jc.2013-4468","volume":"99","author":"MA Nexo","year":"2014","unstructured":"Nexo MA, Watt T, Pedersen J, Bonnema SJ, Heged\u00fcs L, Rasmussen AK et al (2014) Increased risk of long-term sickness absence, lower rate of return to work, and higher risk of unemployment and disability pensioning for thyroid patients: a Danish register-based cohort study. J Clin Endocrinol Metab 99(9):3184\u20133192. https:\/\/doi.org\/10.1210\/jc.2013-4468","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"2653_CR154","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3238\/arztebl.2009.0283","volume":"106","author":"KA Ponto","year":"2009","unstructured":"Ponto KA, Pitz S, Pfeiffer N, Hommel G, Weber MM, Kahaly GJ (2009) Quality of life and occupational disability in endocrine orbitopathy. Dtsch Arztebl Int 106(17):283\u2013289. https:\/\/doi.org\/10.3238\/arztebl.2009.0283","journal-title":"Dtsch Arztebl Int"},{"key":"2653_CR155","doi-asserted-by":"publisher","first-page":"1283374","DOI":"10.3389\/fendo.2023.1283374","volume":"14","author":"TJ Smith","year":"2023","unstructured":"Smith TJ, Heged\u00fcs L, Lesser I, Perros P, Dorris K, Kinrade M et al (2023) How patients experience thyroid eye disease. Front Endocrinol (Lausanne) 14:1283374. https:\/\/doi.org\/10.3389\/fendo.2023.1283374","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2653_CR156","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1210\/jc.2012-3119","volume":"98","author":"KA Ponto","year":"2013","unstructured":"Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ (2013) Public health relevance of graves\u2019 orbitopathy. J Clin Endocrinol Metab 98(1):145\u2013152. https:\/\/doi.org\/10.1210\/jc.2012-3119","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2653_CR157","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40123-021-00385-8","volume":"10","author":"KP Cockerham","year":"2021","unstructured":"Cockerham KP, Padnick-Silver L, Stuertz N, Francis-Sedlak M, Holt RJ (2021) Quality of life in patients with chronic thyroid eye disease in the united States. Ophthalmol Ther 10(4):975\u2013987. https:\/\/doi.org\/10.1007\/s40123-021-00385-8","journal-title":"Ophthalmol Ther"},{"issue":"5","key":"2653_CR158","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1530\/eje.1.01904","volume":"152","author":"F Azizi","year":"2005","unstructured":"Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholesla (2005) Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol 152(5):695\u2013701. https:\/\/doi.org\/10.1530\/eje.1.01904","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2653_CR159","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1089\/thy.2018.0315","volume":"29","author":"O T\u00f6rring","year":"2019","unstructured":"T\u00f6rring O, Watt T, Sj\u00f6lin G, Bystr\u00f6m K, Abraham-Nordling M, Calissendorff J et al (2019) Impaired quality of life after radioiodine therapy compared to antithyroid drugs or surgical treatment for graves\u2019 hyperthyroidism: a long-term follow-up with the thyroid-related patient-reported outcome questionnaire and 36-item short form health status survey. Thyroid 29(3):322\u2013331. https:\/\/doi.org\/10.1089\/thy.2018.0315","journal-title":"Thyroid"},{"key":"2653_CR160","doi-asserted-by":"publisher","unstructured":"Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS (2015) Outcomes in relapsed Graves\u2019 disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid 25(12):1282\u20131290. https:\/\/doi.org\/10.1089\/thy.2015.0195. E","DOI":"10.1089\/thy.2015.0195"},{"issue":"4","key":"2653_CR161","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-15-1099","volume":"174","author":"D Ta\u00efeb","year":"2016","unstructured":"Ta\u00efeb D, Bournaud C, Eberle MC, Catargi B, Schvartz C, Cavarec MB et al (2016) Quality of life, clinical outcomes and safety of early prophylactic Levothyroxine administration in patients with graves\u2019 hyperthyroidism undergoing radioiodine therapy: a randomized controlled study. Eur J Endocrinol 174(4):491\u2013502. https:\/\/doi.org\/10.1530\/EJE-15-1099","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2653_CR162","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1055\/a-2240-8087","volume":"63","author":"R Larisch","year":"2024","unstructured":"Larisch R, Midgley JEM, Dietrich JW, Hoermann R (2024) Effect of radioiodine treatment on quality of life in patients with subclinical hyperthyroidism: a prospective controlled study. Nuklearmedizin 63(3):176\u2013187. https:\/\/doi.org\/10.1055\/a-2240-8087","journal-title":"Nuklearmedizin"},{"issue":"1","key":"2653_CR163","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4274\/mirt.galenos.2024.21548","volume":"34","author":"H Af\u015fin","year":"2025","unstructured":"Af\u015fin H, \u00c7al\u0131\u015fkan B (2025) Quality of life outcomes following radioactive iodine 131 therapy in hyperthyroid patients: insights from the thyroid patient-reported outcome questionnaire. Mol Imaging Radionucl Ther 34(1):38\u201347. https:\/\/doi.org\/10.4274\/mirt.galenos.2024.21548","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"8","key":"2653_CR164","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1089\/thy.2016.0222","volume":"26","author":"JP Brito","year":"2016","unstructured":"Brito JP, Schilz S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, Montori VM (2016) Antithyroid drugs-the most common treatment for graves\u2019 disease in the united states: a nationwide population-based study. Thyroid 26(8):1144\u20131145. https:\/\/doi.org\/10.1089\/thy.2016.0222","journal-title":"Thyroid"},{"issue":"6","key":"2653_CR165","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1530\/EJE-20-1490","volume":"184","author":"CMJ van Kinschot","year":"2021","unstructured":"van Kinschot CMJ, Soekhai VR, de Bekker-Grob EW, Visser WE, Peeters RP, van Ginhoven TM, van Noord C (2021) Preferences of patients and clinicians for treatment of graves\u2019 disease: a discrete choice experiment. Eur J Endocrinol 184(6):803\u2013812. https:\/\/doi.org\/10.1530\/EJE-20-1490","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2653_CR166","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s12020-021-02725-x","volume":"74","author":"SY Park","year":"2021","unstructured":"Park SY, Kim BH, Kim M, Hong AR, Park J, Park H et al (2021) The longer the antithyroid drug is used, the lower the relapse rate in graves\u2019 disease: a retrospective multicenter cohort study in Korea. Endocrine 74(1):120\u2013127. https:\/\/doi.org\/10.1007\/s12020-021-02725-x","journal-title":"Endocrine"},{"issue":"11","key":"2653_CR167","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1089\/thy.2019.0085","volume":"29","author":"G Sj\u00f6lin","year":"2019","unstructured":"Sj\u00f6lin G, Holmberg M, T\u00f6rring O, Bystr\u00f6m K, Khamisi S, de Laval D et al (2019) The long-term outcome of treatment for graves\u2019 hyperthyroidism. Thyroid 29(11):1545\u20131557. https:\/\/doi.org\/10.1089\/thy.2019.0085","journal-title":"Thyroid"},{"issue":"3","key":"2653_CR168","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1210\/clinem\/dgad538","volume":"109","author":"AE Meling Stokland","year":"2024","unstructured":"Meling Stokland AE, Austdal M, Nedreb\u00f8 BG, Carlsen S, Hetland HB, Breivik L et al (2024) Outcomes of patients with graves disease 25 years after initiating antithyroid drug therapy. J Clin Endocrinol Metab 109(3):827\u2013836. https:\/\/doi.org\/10.1210\/clinem\/dgad538","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2653_CR169","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1089\/thy.2017.0681","volume":"28","author":"SJ Peterson","year":"2018","unstructured":"Peterson SJ, Cappola AR, Castro MR, Dayan CM, Farwell AP, Hennessey JV et al (2018) An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid 28(6):707\u2013721. https:\/\/doi.org\/10.1089\/thy.2017.0681","journal-title":"Thyroid"},{"issue":"3","key":"2653_CR170","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/cen.14340","volume":"94","author":"AL Mitchell","year":"2021","unstructured":"Mitchell AL, Heged\u00fcs L, \u017darkovi\u0107 M, Hickey JL, Perros P (2021) Patient satisfaction and quality of life in hypothyroidism: an online survey by the British thyroid foundation. Clin Endocrinol (Oxf) 94(3):513\u2013520. https:\/\/doi.org\/10.1111\/cen.14340","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2653_CR171","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/cen.14473","volume":"98","author":"P Perros","year":"2023","unstructured":"Perros P, Van Der Feltz-Cornelis C, Papini E, Nagy EV, Weetman AP, Heged\u00fcs L (2023) The enigma of persistent symptoms in hypothyroid patients treated with levothyroxine: a narrative review. Clin Endocrinol (Oxf) 98(4):461\u2013468. https:\/\/doi.org\/10.1111\/cen.14473","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2653_CR172","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/cen.14986","volume":"100","author":"Y Li","year":"2024","unstructured":"Li Y, Yang T, Ju L, Feng Y, Chen Z, Xiang X et al (2024) Quality of life and decision regret in patients with late-hypothyroidism after radioiodine treatment for graves\u2019 disease. Clin Endocrinol (Oxf) 100(1):87\u201395. https:\/\/doi.org\/10.1111\/cen.14986","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2653_CR173","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1089\/thy.2023.0580","volume":"34","author":"R Attanasio","year":"2024","unstructured":"Attanasio R, \u017darkovi\u0107 M, Papini E, Nagy EV, Negro R, Perros P et al (2024) Patients\u2019 persistent symptoms, clinician demographics, and geo-economic factors are associated with choice of therapy for hypothyroidism by European thyroid specialists: the THESIS collaboration. Thyroid 34(4):429\u2013441. https:\/\/doi.org\/10.1089\/thy.2023.0580","journal-title":"Thyroid"},{"issue":"7","key":"2653_CR174","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41574-024-00989-7","volume":"20","author":"AC Bianco","year":"2024","unstructured":"Bianco AC, Taylor PN (2024) Optimizing the treatment of hypothyroidism. Nat Rev Endocrinol 20(7):379\u2013380. https:\/\/doi.org\/10.1038\/s41574-024-00989-7","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2653_CR175","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1210\/edrv.21.2.0393","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena L, Pinchera A, Marcocci C (2000) Management of graves\u2019 ophthalmopathy: reality and perspectives. Endocr Rev 21(2):168\u2013199. https:\/\/doi.org\/10.1210\/edrv.21.2.0393","journal-title":"Endocr Rev"},{"issue":"1","key":"2653_CR176","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/clinem\/dgad637","volume":"21","author":"RS Douglas","year":"2023","unstructured":"Douglas RS, Couch S, Wester ST, Fowler BT, Liu CY, Subramanian PS et al (2023) Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab 21(1):25\u201335. https:\/\/doi.org\/10.1210\/clinem\/dgad637","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2653_CR177","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1210\/jc.2013-1954","volume":"98","author":"V Sundaresh","year":"2013","unstructured":"Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS (2013) Comparative effectiveness of therapies for graves\u2019 hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 98(9):3671\u20133677. https:\/\/doi.org\/10.1210\/jc.2013-1954","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02653-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02653-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02653-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T20:52:51Z","timestamp":1757364771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02653-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":177,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2653"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02653-x","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare related to this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}